跳至主要内容
临床试验/JPRN-UMIN000052228
JPRN-UMIN000052228招募中Unknown

Efficacy and safety of initial treatment (combination immunotherapy or chemotherapy + ICI) in advanced non-small cell lung cancer patients (TPS 1-49%): A multicenter retrospective observational study (TOPGAN2023-01) - Efficacy and safety of initial treatment (combination immunotherapy or chemotherapy + ICI) in advanced non-small cell lung cancer patients (TPS 1-49%): A multicenter retrospective observational study (TOPGAN2023-01)

department of respiratory medicine hirosaki university graduate school of medicine0 个研究点目标入组 300 人开始时间: 2023年9月18日最近更新:
适应症

试验速览

阶段
Unknown
状态
招募中
发起方
入组人数
300

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
20years-old 至 100years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1 Positive for genetic mutations (EGFR common mutation/ALK), LCNEC 2 The attending physician has deemed the patient ineligible for registration in this study. 3 Has an active concurrent cancer that affects prognosis

研究者

发起方
department of respiratory medicine hirosaki university graduate school of medicine

相似试验